A Sequence-specific Exopeptidase Activity Test (SSEAT) for “Functional” Biomarker Discovery*S

One form of functional proteomics entails profiling of genuine activities, as opposed to surrogates of activity or active “states,” in a complex biological matrix: for example, tracking enzyme-catalyzed changes, in real time, ranging from simple modifications to complex anabolic or catabolic reactions. Here we present a test to compare defined exoprotease activities within individual proteomes of two or more groups of biological samples. It tracks degradation of artificial substrates, under strictly controlled conditions, using semiautomated MALDI-TOF mass spectrometric analysis of the resulting patterns. Each fragment is quantitated by comparison with double labeled, non-degradable internal standards (all-d-amino acid peptides) spiked into the samples at the same time as the substrates to reflect adsorptive and processing-related losses. The full array of metabolites is then quantitated (coefficients of variation of 6.3–14.3% over five replicates) and subjected to multivariate statistical analysis. Using this approach, we tested serum samples of 48 metastatic thyroid cancer patients and 48 healthy controls, with selected peptide substrates taken from earlier standard peptidomics screens (i.e. the “discovery” phase), and obtained class predictions with 94% sensitivity and 90% specificity without prior feature selection (24 features). The test all but eliminates reproducibility problems related to sample collection, storage, and handling as well as to possible variability in endogenous peptide precursor levels because of hemostatic alterations in cancer patients.

[1]  E. Diamandis Oncopeptidomics: a useful approach for cancer diagnosis? , 2007, Clinical chemistry.

[2]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[3]  P. Budde,et al.  Oncopeptidomics--a commentary on opportunities and limitations. , 2007, Cancer letters.

[4]  K. Coombes,et al.  Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. , 2005, Journal of proteome research.

[5]  P. Vincent Blood: Textbook of Hematology , 1998 .

[6]  Richard D. Smith,et al.  Advances and Challenges in Liquid Chromatography-Mass Spectrometry-based Proteomics Profiling for Clinical Applications* , 2006, Molecular & Cellular Proteomics.

[7]  G. Sledge,et al.  Extracellular proteolysis and cancer: meeting summary and future directions. , 2003, Cancer research.

[8]  J. Baron,et al.  The Molecular Basis of Blood Diseases , 1994 .

[9]  P. Tempst,et al.  Serum Peptidome Patterns That Distinguish Metastatic Thyroid Carcinoma from Cancer-free Controls Are Unbiased by Gender and Age*S , 2006, Molecular & Cellular Proteomics.

[10]  P. Tempst,et al.  Lethal Effects of Apidaecin on Escherichia coliInvolve Sequential Molecular Interactions with Diverse Targets* , 1999, The Journal of Biological Chemistry.

[11]  M. Mann,et al.  Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.

[12]  B. Cravatt,et al.  Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype , 2002, Nature Biotechnology.

[13]  G. Goldsmith Hemostatic Changes in Patients with Malignancy , 2001, International journal of hematology.

[14]  Dai,et al.  Platelet activation. , 2020, Arteriosclerosis.

[15]  R. Bick Coagulation Abnormalities in Malignancy: A Review , 1992, Seminars in thrombosis and hemostasis.

[16]  E. Diamandis Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[17]  J. Yates,et al.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.

[18]  S. Patterson,et al.  Does the serum peptidome reveal hemostatic dysregulation? , 2007, Ernst Schering Research Foundation workshop.

[19]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[20]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[21]  O. Jensen Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. , 2004, Current opinion in chemical biology.

[22]  E. Petricoin,et al.  The blood peptidome: a higher dimension of information content for cancer biomarker discovery , 2006, Nature Reviews Cancer.

[23]  Nasreen S Jessani,et al.  A streamlined platform for high-content functional proteomics of primary human specimens , 2005, Nature Methods.

[24]  X. Puente,et al.  Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.

[25]  P. Tempst,et al.  Correcting common errors in identifying cancer-specific serum peptide signatures. , 2005, Journal of proteome research.

[26]  Matthew Bogyo,et al.  Activity-based probes that target diverse cysteine protease families , 2005, Nature chemical biology.

[27]  Hartmut Selle,et al.  The Process Chain for Peptidomic Biomarker Discovery , 2006, Disease markers.

[28]  R. Silverstein,et al.  Hypercoagulability in cancer. , 1996, Hematology/oncology clinics of North America.

[29]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[30]  H. Erdjument-Bromage,et al.  Biodiversity of apidaecin-type peptide antibiotics. Prospects of manipulating the antibacterial spectrum and combating acquired resistance. , 1994, The Journal of biological chemistry.

[31]  Massimo Pandolfo,et al.  Molecular Basis , 2022 .

[32]  B. Kemp,et al.  Active site-directed protein regulation , 1999, Nature.

[33]  B. Alberts,et al.  Molecular Biology of the Cell 4th edition , 2007 .

[34]  P. Marx Thrombin-activatable fibrinolysis inhibitor. , 2004, Current medicinal chemistry.

[35]  Erika Check,et al.  Proteomics and cancer: Running before we can walk? , 2004, Nature.

[36]  Paul Tempst,et al.  Data analysis of assorted serum peptidome profiles , 2007, Nature Protocols.

[37]  Bonnie F. Sloane,et al.  Proteases, extracellular matrix, and cancer: a workshop of the path B study section. , 2004, The American journal of pathology.

[38]  R. Fisher,et al.  Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Gygi,et al.  Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Burlingame,et al.  Chemical Approaches for Functionally Probing the Proteome* , 2002, Molecular & Cellular Proteomics.

[41]  M. Levine,et al.  Hemostatic alterations in cancer patients , 2005, Cancer and Metastasis Reviews.

[42]  P. Tempst,et al.  Automated serum peptide profiling , 2006, Nature Protocols.

[43]  George G Klee,et al.  Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. , 2004, Journal of proteome research.

[44]  E. Holland,et al.  Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.

[45]  F. Rickles,et al.  Activation of blood coagulation in cancer: Trousseau's syndrome revisited. , 1983, Blood.